Tumors with deep myometrial invasion (>1/2 myometrial depth) (19.4 vs. 12.9, p = 0.028), positive LVSI (17.2 vs. 13.0, p = 0.042), lymph node metastasis (34.1 vs. 12.1, p < 0.01), and advanced FIGO stages (stage III/IV) (25.7 vs. 12.7, p = 0.017) (all by one-way ANOVA) had significantly higher expression levels of uPA compared to those with superficial myometrial invasion (<1/2 myometrial invasion), negative LVSI, no lymph node metastasis, and early FIGO stages (stage I/II) in the training set (Table 3). The gene discussed is PLAU; the disease is metastatic malignant neoplasm in the lymph nodes.